These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16329138)

  • 21. Epothilones in prostate cancer: review of clinical experience.
    Dawson NA
    Ann Oncol; 2007 Jul; 18 Suppl 5():v22-7. PubMed ID: 17656558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
    Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
    Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    Petrylak DP; Ankerst DP; Jiang CS; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    J Natl Cancer Inst; 2006 Apr; 98(8):516-21. PubMed ID: 16622120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone.
    Caffo O; Sava T; Comploj E; Giampaolo MA; Segati R; Valduga F; Cetto G; Galligioni E
    Urol Oncol; 2010; 28(2):152-6. PubMed ID: 18848786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
    J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
    Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
    Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
    Smaletz O; Galsky M; Scher HI; DeLaCruz A; Slovin SF; Morris MJ; Solit DB; Davar U; Schwartz L; Kelly WK
    Ann Oncol; 2003 Oct; 14(10):1518-24. PubMed ID: 14504052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J
    Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.